Skip to main content
BIDE PHARMATECH CO., LTD. logo

BIDE PHARMATECH CO., LTD. - Investor Relations & Filings

Listed IPO Oct 2022
Ticker · 688073 ISIN · CNE100005NV3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 495 across all filing types
Latest filing 2026-04-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688073 · 1 venue

Key figures FY2025

Period ended 2025-12-31 · CNY
Headline annual figures for BIDE PHARMATECH CO., LTD., fiscal year 2025, reported in CNY, with the source filing for each figure.
Total Revenues CNY 132.38M per the Audit Report / Information filed 2026-05-08
Net Income CNY 15.17M per the Audit Report / Information filed 2026-05-08
Total Assets CNY 251.68M per the Audit Report / Information filed 2026-05-08
Total Equity CNY 204.54M per the Audit Report / Information filed 2026-05-08
Cash from Ops CNY 2.83M per the Audit Report / Information filed 2026-05-08

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About BIDE PHARMATECH CO., LTD.

https://www.bidepharmatech.com/

Bide Pharmatech Co., Ltd. specializes in the research, development, and supply of high-quality chemical building blocks and specialty reagents for the global pharmaceutical and biotechnology sectors. The company offers an extensive portfolio of small molecule organic compounds, including functionalized heterocycles, catalysts, ligands, and advanced intermediates essential for drug discovery and chemical research. Bide Pharmatech provides comprehensive services ranging from catalog product distribution to custom synthesis and contract research, supporting clients through various stages of the drug development lifecycle. With a focus on technical innovation and rigorous quality control, the firm facilitates efficient lead optimization and process development for academic institutions and commercial laboratories worldwide.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guotai Huatong Securities Co., Ltd.) regarding the listing and circulation of certain restricted shares of Shanghai Bide Pharmaceutical Technology Co., Ltd. It discusses the types and quantities of restricted shares, lock-up periods, shareholder commitments, and compliance with relevant securities regulations. The document is not a financial report, earnings release, or management discussion, but rather a formal regulatory compliance and verification statement related to the unlocking and circulation of restricted shares after an IPO. This type of document fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance announcement that does not fit other more specific categories like Capital/Financing Update or Major Shareholding Notification. The document length and content confirm it is not a brief announcement but a substantive regulatory filing.
2026-04-02 Chinese
国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司使用自有资金支付募投项目所需资金并以募集资金等额置换的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Guotai Huarong Securities Co., Ltd. regarding the use of self-owned funds to pay for investment projects and the equivalent replacement with raised funds by Shanghai Bide Pharmaceutical Technology Co., Ltd. It references regulatory approvals, fundraising details, project investment plans, internal controls, and board meeting resolutions. The document is a formal verification or audit opinion related to the use of raised funds and compliance with relevant securities regulations. It does not contain financial statements or quarterly/yearly financial results, nor is it a simple announcement or presentation. It is a standalone audit or verification report focusing on compliance and fund usage, fitting the category of Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and is not merely an announcement or certification letter, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. Q1 2026
2026-03-09 Chinese
关于使用自有资金支付募投项目所需资金并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanghai Bide Pharmaceutical Technology Co., Ltd. regarding the use of its own funds to pay for investment projects initially funded by raised capital, and the subsequent replacement of those funds with the raised capital. It details the background of the fundraising, the projects involved, the reasons for using own funds temporarily, the operational process, and the impact on the company. It also includes the board's approval and the sponsor's verification opinion. The document is relatively short (3119 characters) and is structured as a formal announcement rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or analysis but focuses on a specific capital usage update related to fundraising and capital management. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-03-09 Chinese
2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the formal annual report. The document is relatively short (1765 characters) and serves as a quick earnings update rather than a full comprehensive report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is preliminary. It is also not a Report Publication Announcement (RPA) because it contains actual financial data, not just a notice of report availability. FY 2025
2026-02-27 Chinese
关于股东权益变动触及1%刻度的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding percentage by certain shareholders of Shanghai Bide Pharmaceutical Technology Co., Ltd. It details the reduction in shareholding by specific investors, the percentage changes before and after the transaction, and confirms that the change does not trigger mandatory tender offer obligations. The document is titled as an "Announcement" and is focused on shareholding changes touching the 1% threshold. It does not contain financial statements, earnings data, or management discussion. It is not a report but an announcement of shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short (2310 characters), consistent with an announcement rather than a full report.
2026-02-13 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions from an extraordinary shareholders' meeting held by Shanghai Bide Pharmaceutical Technology Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is short (1381 characters), and it serves as an official notice of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-02-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.